Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 721 to 735 of 8885 results

  1. Brain cancers

    All NICE products on brain cancers. Includes any guidance, advice and quality standards.

  2. Breast cancer

    All NICE products on breast cancer. Includes any guidance, advice and quality standards.

  3. Staffing

    All NICE products on staffing. Includes any guidance.

  4. Organ and tissue transplantation

    All NICE products on organ and tissue transplantation. Includes any guidance, advice and quality standards.

  5. Pressure ulcers

    All NICE products on pressure ulcers. Includes any guidance, advice and quality standards.

  6. Urinary tract infection

    All NICE products on urinary tract infection. Includes any guidance, advice and quality standards.

  7. Lower urinary tract symptoms

    All NICE products on lower urinary tract symptoms. Includes any guidance, advice and quality standards.

  8. Parkinson's disease, tremor and dystonia

    All NICE products on parkinson's disease, tremor and dystonia. Includes any guidance, advice and quality standards.

  9. Mesothelioma

    All NICE products on mesothelioma. Includes any guidance.

  10. Vulnerable groups

    All NICE products on vulnerable groups. Includes any guidance and quality standards.

  11. People with physical disabilities

    All NICE products on people with physical disabilities. Includes any guidance.

  12. Schools and other educational settings

    All NICE products on schools and other educational settings. Includes any guidance and quality standards.

  13. Community settings

    All NICE products on community settings. Includes any guidance and quality standards.

  14. Serious eye disorders (QS180)

    This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.

  15. Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]

    In development Reference number: GID-TA11232 Expected publication date:  29 April 2026